| abstract |
Stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. Methods for preparing such formulations and methods of using such formulations. Claim 1: A stable aqueous pharmaceutical formulation, characterized in that it comprises an anti-PDL1 monoclonal antibody in a concentration of about 40 mg / ml to about 125 mg / ml, histidine acetate or sodium acetate in a concentration of about 15 mM to about 25 mM, sucrose in a concentration of about 60 mM to about 240 mM, polysorbate in a concentration of about 0.005% (w / v) to about 0.06% (w / v) and a pH of about 5.0 to about 6.3. |